Abstract
Background Congenital cytomegalovirus disease (cCMV) can be severe but is uncommon. Investigations of the role of genome sequence variation in the causative virus (human cytomegalovirus, HCMV) in clinical outcome have to date depended on small sample numbers derived from fresh tissues. Extensive formalin-fixed, paraffin-embedded (FFPE) cCMV biorepositories established worldwide potentially provide much larger sample numbers for future investigations. However, there are no published reports of sequencing whole HCMV genomes from such material.
Objective To sequence whole HCMV genomes from cCMV FFPE material.
Study design Sixteen FFPE samples of foetal kidney or placental tissue were processed from ten cCMV cases in foetuses or neonates. Two commercial kits for extracting DNA from FFPE material were evaluated, HCMV DNA was enriched in the extracts, and the samples were sequenced on the Illumina platform. The sequence read datasets were analysed by genotyping, genome assembly and variant calling using a published software pipeline.
Results Whole HCMV genomes were sequenced for five cases using either DNA extraction kit.
Conclusions Sequencing whole HCMV genomes from cCMV FFPE material is feasible. This potentially facilitates future studies of the effects of HCMV variation on the clinical outcome of cCMV.
Highlights
Human cytomegalovirus (HCMV) causes congenital cytomegalovirus disease (cCMV).
cCMV samples exist in formalin-fixed, paraffin-embedded (FFPE) biorepositories.
Sequencing whole HCMV genomes from such material is feasible.
This may aid future studies on the effect of HCMV diversity on cCMV outcomes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
K.K.L. received funding award from Medical Research Council, grant number MC_ST_00034. A.J.D. received funding from Medical Research Council, grant numbers: MC_UU_12014/3 and MC_UU_12014/12 and from Wellcome, grant number 204870/Z/16/Z. Funder websites are as follows: https://www.ukri.org/councils/mrc/ and https://wellcome.org/. Neither of the funding bodies had any role in the study design, data collection and analysis, decision to publish, nor preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was granted by the Health Research Authority Research Ethics Committee (HRA REC reference 18/LO/1441; R&D number 18/BW/NNU/NO17; 31 August 2018), and informed consent was not required as no patient-identifiable information was collected. The authors had no access to patient-identifiable data during or after the study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Read datasets and HCMV genome sequences are available from NCBI BioProject PRJNA1181764, NCBI Sequence Read Archive (SRA) and NCBI GenBank, respectively, under the accessions listed in Table 2 of the manuscript.